Press Releases
December 2, 2022
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 30, 2022
Iveric Bio Announces Proposed Offering of Common Stock
November 30, 2022
Iveric Bio Announces Pricing of $300 Million Public Offering of Common Stock
November 17, 2022
Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy
November 4, 2022
Iveric Bio to Present at Upcoming Investor Conferences
November 3, 2022
Iveric Bio Reports Third Quarter 2022 Operational Highlights and Financial Results
November 3, 2022
Iveric Bio Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy
November 2, 2022
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 27, 2022
Iveric Bio to Report Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 3, 2022
October 4, 2022